IP Library › Granted Patent US 12,270,813
Granted Patent B2
US 12,270,813 · App. 16/620,459 · Granted Apr 8, 2025

Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Inventor: Ugur Sahin (Mainz, DE)
Assignee: BioNTech SE
G01N33/68A61K39/0011A61K39/001156A61K39/001188A61K2039/53A61K2039/876G01N2333/70514G01N2333/70517G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,270,813
App. No.
16/620,459
Granted
Apr 8, 2025
Kind
B2
Abstract

The present invention relates to methods for predicting whether peptides or polypeptides comprising disease specific amino acid modifications, in particular tumor-associated neo-antigens, comprise epitopes, in particular tumor-associated neo-epitopes, which are useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

Claims (91)

1. A method of making a cancer vaccine, the method comprising steps of:

for at least one cancer-specific amino acid modification within a peptide or polypeptide expressed in a cancer cell, determining whether the same or different fragments of the peptide or polypeptide, each of which fragment(s) comprises the same cancer-specific amino acid modification, meet selection criteria in that the same or different fragments:

(I) are presented by MHC molecules of different classes, and/or

(II) when presented by MHC molecules, are reactive with T cells restricted to different MHC classes;

selecting the cancer-specific amino acid modification if the same or different fragments meet the selection criteria; and

producing a vaccine that comprises (a) the peptide or polypeptide comprising the selected cancer-specific amino acid modification or a fragment thereof that meets the selection criteria; or (b) a nucleic acid encoding the peptide, polypeptide, or fragment of (a).

2. The method of claim 1 , wherein the MHC molecules of different classes are MHC class I molecules and MHC class II molecules and/or the T cells restricted to different MHC classes are CD4+ and CD8+ T cells.

3. A method of making a cancer vaccine, the method comprising steps of:

for at least one cancer-specific amino acid modification within a peptide or polypeptide expressed in a cancer cell, determining whether the same or different fragments of the peptide or polypeptide, each of which fragment(s) comprises the same cancer-specific amino acid modification, meet selection criteria in that the same or different fragments:

(I) when presented by the same MHC molecule, are reactive with T cells having different T cell receptors;

selecting the cancer-specific amino acid modification if the same or different fragments meet the selection criteria; and

producing a vaccine that comprises (a) the peptide or polypeptide comprising the selected cancer-specific amino acid modification or a fragment thereof that meets the selection criteria; or

(b) a nucleic acid encoding the peptide, polypeptide, or fragment of (a).

4. The method of claim 3 , wherein the different T cell receptors are of different clonotypes.

5. A method of making a cancer vaccine, the method comprising steps of:

for at least one cancer-specific amino acid modification within a peptide or polypeptide expressed in a cancer cell, determining whether the same or different fragments of the peptide or polypeptide, each of which fragment(s) comprises the same cancer specific amino acid modification, meet selection criteria in that the same or different fragments:

(I) are presented by different MHC molecules of the same class, and/or

(II) when presented by different MHC molecules of the same class, are reactive with different T cells restricted to the same MHC class;

selecting the cancer-specific amino acid modification if the same or different fragments meet the selection criteria; and

producing a vaccine that comprises (a) the peptide or polypeptide comprising the selected cancer-specific amino acid modification or a fragment thereof that meets the selection criteria; or (b) a nucleic acid encoding the peptide, polypeptide, or fragment of (a).

6. The method of claim 5 , wherein the different MHC molecules of the same class are different MHC class I molecules and/or the different T cells restricted to the same MHC class are different CD8+ T cells.

7. A method for making a cancer vaccine, the method comprising steps of:

for at least one cancer-specific amino acid modification within a peptide or polypeptide expressed in a cancer cell, determining whether the same or different fragments of the peptide or polypeptide, each of which fragment(s) comprises the same cancer-specific amino acid modification, meet at least two sets of selection criteria (A), (B), and (C), in that the same or different fragments:

according to the selection criteria (A),

(I) are presented by MHC molecules of different classes, and/or

(II) when presented by MHC molecules, are reactive with T cells restricted to different MHC classes;

according to the selection criteria (B),

(I) when presented by the same MHC molecule, are reactive with T cells having different T cell receptors, and/or

according to the selection criteria (C),

(I) are presented by different MHC molecules of the same class, and/or

(II) when presented by different MHC molecules of the same class, are reactive with different T cells restricted to the same MHC class;

selecting the cancer-specific amino acid modification if the same or different fragments meet at least two sets of the selection criteria (A), (B), and (C); and

producing a vaccine that comprises (a) the peptide or polypeptide comprising the selected cancer-specific amino acid modification or a fragment thereof that meets at least two sets of the selection criteria (A), (B), and (C); or (b) a nucleic acid encoding the peptide, polypeptide, or fragment of (a).

8. The method of claim 7 , wherein the MHC molecules of different classes are MHC class I molecules and MHC class II molecules and/or the T cells restricted to different MHC classes are CD4+ and CD8+ T cells.

9. The method of claim 7 , comprising steps of:

for the at least one cancer-specific amino acid modification, determining whether the same or different fragments of the peptide or polypeptide, each of which fragment(s) comprises the same cancer-specific amino acid modification, meet all three sets of the selection criteria (A), (B), and (C);

selecting the cancer-specific amino acid modification if the same or different fragments meet all three sets of the selection criteria (A), (B), and (C); and

producing a vaccine that comprises (a) the peptide or polypeptide comprising the selected cancer-specific amino acid modification or a fragment thereof that meets all three sets of the selection criteria (A), (B), and (C); or (b) a nucleic acid encoding the peptide, polypeptide, or fragment of (a).

10. The method of claim 7 or 9 , wherein the different T cell receptors are of different clonotypes.

11. The method of claim 7 or 9 , wherein the different MHC molecules of the same class are different MHC class I molecules and/or the different T cells restricted to the same MHC class are different CD8+ T cells.

12. A method of making a cancer vaccine, the method comprising steps of:

(i) identifying a plurality of cancer-specific amino acid modifications within peptides and/or polypeptides expressed in cancer cells;

(ii) determining, for each cancer-specific amino acid modification in the plurality, whether the same or different fragments of the corresponding peptide or polypeptide, each of which fragment(s) comprises the same cancer-specific amino acid modification, meet the selection criteria in that the same or different fragments:

(I) are presented by MHC molecules of different classes; and/or

(II) when presented by MHC molecules, are reactive with T cells restricted to different MHC classes;

(iii) ranking the level of MHC presentation and/or T cell reactivity for each of the cancer-specific amino acid modifications in the plurality based on the determination of (ii);

(iv) selecting at least one of the cancer-specific amino acid modifications if the same or different fragments comprising the cancer-specific amino acid modification meet the selection criteria and if the cancer-specific amino acid modification has a ranking that is higher than that of at least one of the other cancer-specific amino acid modifications in the plurality; and

(v) producing a vaccine that comprises (a) a peptide or polypeptide comprising the selected cancer-specific amino acid modification, or a fragment thereof; or (b) a nucleic acid encoding the peptide.

13. The method of claim 12 , wherein the MHC molecules of different classes are MHC class I molecules and MHC class II molecules and/or the T cells restricted to different MHC classes are CD4+ and CD8+ T cells.

14. A method of making a cancer vaccine, the method comprising steps of:

(i) identifying a plurality of cancer-specific amino acid modifications within peptides and/or polypeptides expressed in cancer cells;

(ii) determining, for each cancer-specific amino acid modification in the plurality, whether the same or different fragments of the corresponding peptide or polypeptide, each of which fragment(s) comprises the same cancer specific amino acid modification, meet selection criteria in that the same or different fragments, when presented by the same MHC molecule, are reactive with T cells having different T cell receptors;

(iii) ranking the level of MHC presentation and/or T cell reactivity for each of the cancer-specific amino acid modifications in the plurality based on the determination of (ii);

(iv) selecting at least one of the cancer-specific amino acid modifications if the same or different fragments comprising the cancer-specific amino acid modification meet the selection criteria and if the cancer-specific amino acid modification has a ranking that is higher than that of at least one of the other cancer-specific amino acid modifications in the plurality; and

(v) producing a vaccine that comprises (a) a peptide or polypeptide comprising the selected cancer-specific amino acid modification, or a fragment thereof; or (b) a nucleic acid encoding the peptide, polypeptide, or fragment of (a).

15. The method of claim 14 , wherein the different T cell receptors are of different clonotypes.

16. A method of making a cancer vaccine, the method comprising:

(i) identifying a plurality of cancer-specific amino acid modifications within peptides and/or polypeptides expressed in cancer cells;

(ii) determining, for each cancer-specific amino acid modification in the plurality, whether the same or different fragments of the corresponding peptide or polypeptide, each of which fragment(s) comprises the same cancer-specific amino acid modification, meet selection criteria in that the same or different fragments:

(I) are presented by different MHC molecules of the same class; and/or

(II) when presented by different MHC molecules of the same class, are reactive with different T cells restricted to the same MHC class;

(iii) ranking the level of MHC presentation and/or T cell reactivity for each of the cancer-specific amino acid modifications in the plurality based on the determination of (ii);

(iv) selecting at least one of the cancer-specific amino acid modifications if the same or different fragments comprising the cancer-specific amino acid modification meet the selection criteria and if the cancer-specific amino acid modification has a ranking that is higher than that of at least one of the other cancer-specific amino acid modifications in the plurality; and

(v) producing a vaccine that comprises (a) a peptide or polypeptide comprising the selected cancer-specific amino acid modification, or a fragment thereof; or (b) a nucleic acid encoding the peptide, polypeptide, or fragment of (a).

17. The method of claim 16 , wherein the different MHC molecules of the same class are different MHC class I molecules and/or the different T cells restricted to the same MHC class are different CD8+ T cells.

18. A method of making a cancer vaccine, the method comprising:

(i) identifying a plurality of cancer specific amino acid modifications within peptides and/or polypeptides expressed in cancer cells;

(ii) determining, for each cancer-specific amino acid modification in the plurality, whether the same or different fragments of the corresponding peptide or polypeptide, each of which fragment(s) comprises the same cancer-specific amino acid modification, meet at least two sets of selection criteria (A), (B), and (C), in that the same or different fragments:

according to the selection criteria (A),

(I) are presented by MHC molecules of different classes and/or

(II) when presented by MHC molecules, are reactive with T cells restricted to different MHC classes,

according to the selection criteria (B),

(I) when presented by the same MHC molecule, are reactive with T cells having different T cell receptors, and/or

according to the selection criteria (C),

(I) are presented by different MHC molecules of the same class, and/or

(II) when presented by different MHC molecules of the same class, are reactive with different T cells restricted to the same MHC class,

(iii) ranking the level of MHC presentation and/or T cell reactivity for each of the cancer-specific amino acid modifications in the plurality based on the determination of (ii);

(iv) selecting at least one of the cancer-specific amino acid modifications if the same or different fragments comprising the cancer-specific amino acid modification meet at least two sets of the selection criteria (A), (B), and (C), and if the cancer-specific amino acid modification has a ranking that is higher than that of at least one of the other cancer-specific amino acid modifications in the plurality; and

(v) producing a vaccine that comprises (a) a peptide or polypeptide comprising the selected cancer-specific amino acid modification, or a fragment thereof; or (b) a nucleic acid encoding the peptide, polypeptide, or fragment of (a).

19. The method of claim 18 , wherein the MHC molecules of different classes are MHC class I molecules and MHC class II molecules and/or the T cells restricted to different MHC classes are CD4+ and CD8+ T cells.

20. The method of claim 18 , comprising steps of:

(ii) determining, for each cancer-specific amino acid modification in the plurality, whether the same or different fragments of the corresponding peptide or polypeptide, each of which fragment(s) comprises the same cancer-specific amino acid modification, meet all three sets of the selection criteria (A), (B), and (C), and

(iii) ranking the level of MHC presentation and/or T cell reactivity for each of the cancer-specific amino acid modifications in the plurality based on the determination of (ii);

(iv) selecting at least one of the cancer-specific amino acid modifications if the same or different fragments comprising the cancer-specific amino acid modification meet all three sets of the selection criteria (A), (B), and (C), and if the cancer-specific amino acid modification has a ranking that is higher than that of at least one of the other cancer-specific amino acid modifications in the plurality; and

(v) producing a vaccine that comprises (a) a peptide or polypeptide comprising the selected cancer-specific amino acid modification, or a fragment thereof; or (b) a nucleic acid encoding the peptide, polypeptide, or fragment of (a).

21. The method of claim 18 or 20 , wherein the different T cell receptors are of different clonotypes.

22. The method of claim 18 or 20 , wherein the different MHC molecules of the same class are different MHC class I molecules and/or the different T cells restricted to the same MHC class are different CD8+ T cells.

23. The method of any one of claims 12, 14, 16, 18, and 20 , wherein the different amino acid modifications determined in step (ii) are present in the same and/or in different peptides or polypeptides.

24. The method of any one of claims 12, 14, 16, 18, and 20 , wherein the step of ranking comprises assigning a score to each of the cancer-specific amino acid modifications based on the determination of (ii) and comparing the scores obtained for each of the amino acid modifications determined in (ii).

25. The method of any one of claims 1, 3, 5, 7, 9, 12, 14, 16, 18, and 20 , wherein the cancer-specific amino acid modification(s) is (are) cancer-specific somatic mutation(s).

26. The method of any one of claims 1, 3, 5, 7, 9, 12, 14, 16, 18, and 20 , wherein the fragment(s) comprising the cancer-specific amino acid modification is a MHC binding peptide or a potential MHC binding peptide or can be processed to provide a MHC binding peptide or a potential MHC binding peptide.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Nov 19, 2021
From: BIONTECH RNA PHARMACEUTICALS GMBH; BIONTECH SE
To: BIONTECH SE
Reel/Frame 058215/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2020
From: SAHIN, UGUR
To: BIONTECH RNA PHARMACEUTICALS GMBH
Reel/Frame 052060/0017 →
Priority Claims (1)
WO PCT/EP2017/064140 · Jun 9, 2017 · international
Continuity (1)
Related Publication 20200209251A1 · Jul 2, 2020
References Cited (400)
US 4897355A · Eppstein et al. · 1990 [cited by applicant]
US 5264618A · Felgner et al. · 1993 [cited by applicant]
US 5703055A · Felgner et al. · 1997 [cited by applicant]
US 6251399B1 · Diamond et al. · 2001 [cited by applicant]
US 6472176B2 · Kovesdi et al. · 2002 [cited by applicant]
US 6500641B1 · Chen et al. · 2002 [cited by applicant]
US 6586410B1 · Wheeler et al. · 2003 [cited by applicant]
US 7303881B2 · Huang et al. · 2007 [cited by applicant]
US 7462354B2 · Sette et al. · 2008 [cited by applicant]
US 7790696B2 · Gregoriadis · 2010 [cited by applicant]
US 8140270B2 · Kingsmore et al. · 2012 [cited by applicant]
US 8217016B2 · Hoerr et al. · 2012 [cited by applicant]
US 8349558B2 · Fatho et al. · 2013 [cited by applicant]
US 8703142B2 · Diamond et al. · 2014 [cited by applicant]
US 8853283B2 · Platscher et al. · 2014 [cited by applicant]
US 8877206B2 · Chen et al. · 2014 [cited by applicant]
US 9115402B2 · Hacohen et al. · 2015 [cited by applicant]
US 10055540B2 · Yelensky et al. · 2018 [cited by applicant]
US 10738355B2 · Sahin et al. · 2020 [cited by applicant]
US 11156617B2 · Sahin · 2021 [cited by examiner]
US 11222711B2 · Sahin et al. · 2022 [cited by applicant]
US 11248264B2 · Sahin · 2022 [cited by examiner]
US 20060188490A1 · Hoerr et al. · 2006 [cited by applicant]
US 20060204523A1 · Khromykh et al. · 2006 [cited by applicant]
US 20070025968A1 · Van Der Burg et al. · 2007 [cited by applicant]
US 20080171711A1 · Hoerr et al. · 2008 [cited by applicant]
US 20090055944A1 · Korman et al. · 2009 [cited by applicant]
US 20090217401A1 · Korman et al. · 2009 [cited by applicant]
US 20090298056A1 · Mautner et al. · 2009 [cited by applicant]
US 20100151492A1 · Ahmed et al. · 2010 [cited by applicant]
US 20100304989A1 · Von Hoff et al. · 2010 [cited by applicant]
US 20110195090A1 · Dimitrov · 2011 [cited by applicant]
US 20110257890A1 · Weinschenk et al. · 2011 [cited by applicant]
US 20120237975A1 · Schrum et al. · 2012 [cited by applicant]
US 20130115272A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130123481A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130156849A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130203115A1 · Schrum et al. · 2013 [cited by applicant]
US 20130237593A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130237594A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130244278A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130244279A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130245106A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130245107A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130255281A1 · Bray · 2013 [cited by applicant]
US 20130266640A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20140010861A1 · Bancel et al. · 2014 [cited by applicant]
US 20140147454A1 · Chakraborty et al. · 2014 [cited by applicant]
US 20140178438A1 · Sahin et al. · 2014 [cited by applicant]
US 20150017211A1 · de Fougerolles et al. · 2015 [cited by applicant]
US 20150030576A1 · Bancel · 2015 [cited by applicant]
US 20150167017A1 · Roy et al. · 2015 [cited by applicant]
US 20160125129A1 · Sahin et al. · 2016 [cited by applicant]
US 20170016075A1 · Velculescu et al. · 2017 [cited by applicant]
US 20190250166A1 · Sahin et al. · 2019 [cited by applicant]
US 20210164034A1 · Sahin et al. · 2021 [cited by applicant]
US 20220074948A1 · Sahin et al. · 2022 [cited by applicant]
US 20220093209A1 · Sahin et al. · 2022 [cited by applicant]
US 20220282322A1 · Sahin et al. · 2022 [cited by applicant]
CN 1237909A · 1999 [cited by applicant]
CN 1440462A · 2003 [cited by applicant]
CN 103180730A · 2013 [cited by applicant]
CN 103608033B · 2016 [cited by applicant]
EP 242108A2 · 1987 [cited by applicant]
EP 0839912A1 · 1998 [cited by applicant]
EP 1242108A1 · 2002 [cited by applicant]
EP 1392341A2 · 2004 [cited by applicant]
EP 2100620A1 · 2009 [cited by applicant]
EP 2569633A2 · 2013 [cited by applicant]
EP 3256853A1 · 2017 [cited by applicant]
EP 3473267A1 · 2019 [cited by applicant]
JP 2004527213A · 2004 [cited by applicant]
JP 2006518982A · 2006 [cited by applicant]
JP 2007501200A · 2007 [cited by applicant]
JP 2010540672A · 2010 [cited by applicant]
JP 2011135874A · 2011 [cited by applicant]
JP 2014523406A · 2014 [cited by applicant]
WO WO1994023031A1 · 1994 [cited by applicant]
WO WO9633739A1 · 1996 [cited by applicant]
WO WO9724447A1 · 1997 [cited by applicant]
WO WO9740156A1 · 1997 [cited by applicant]
WO WO9740852A1 · 1997 [cited by applicant]
WO WO9816238A2 · 1998 [cited by applicant]
WO WO1998014464A1 · 1998 [cited by applicant]
WO WO1999024566A1 · 1999 [cited by applicant]
WO WO9934014A2 · 1999 [cited by applicant]
WO WO9934015A2 · 1999 [cited by applicant]
WO WO1999052503A2 · 1999 [cited by applicant]
WO WO200020029A1 · 2000 [cited by applicant]
WO WO2000067761A1 · 2000 [cited by applicant]
WO WO0119408A1 · 2001 [cited by applicant]
WO WO0129233A2 · 2001 [cited by applicant]
WO WO01047541A1 · 2001 [cited by applicant]
WO WO2001047959A2 · 2001 [cited by applicant]
WO WO0155393A2 · 2001 [cited by applicant]
WO WO0182963A2 · 2001 [cited by applicant]
WO WO2001093902A2 · 2001 [cited by applicant]
WO WO0212281A2 · 2002 [cited by applicant]
WO WO2002048377A2 · 2002 [cited by applicant]
WO WO2002083714A2 · 2002 [cited by applicant]
WO WO02098443A2 · 2002 [cited by applicant]
WO WO2003051401A2 · 2003 [cited by applicant]
WO WO03059381A2 · 2003 [cited by applicant]
WO WO03070162A2 · 2003 [cited by applicant]
WO WO2003068257A1 · 2003 [cited by applicant]
WO WO03078595A2 · 2003 [cited by applicant]
WO WO2003106692A2 · 2003 [cited by applicant]
WO WO2004004743A1 · 2004 [cited by applicant]
WO WO2004031230A2 · 2004 [cited by applicant]
WO WO2005016376A1 · 2005 [cited by applicant]
WO WO2005023295A2 · 2005 [cited by applicant]
WO WO2005028505A2 · 2005 [cited by applicant]
WO WO2005030250A2 · 2005 [cited by applicant]
WO WO2005039533A1 · 2005 [cited by applicant]
WO WO2005040816A1 · 2005 [cited by applicant]
WO WO2005100390A2 · 2005 [cited by applicant]
WO WO2005110338A2 · 2005 [cited by applicant]
WO WO2006121168A1 · 2006 [cited by applicant]
WO WO2007024708A2 · 2007 [cited by applicant]
WO WO2007025760A2 · 2007 [cited by applicant]
WO WO2007031222A2 · 2007 [cited by applicant]
WO WO2007036366A2 · 2007 [cited by applicant]
WO WO2007101227A2 · 2007 [cited by applicant]
WO WO2007106545A2 · 2007 [cited by applicant]
WO WO2008080468A1 · 2008 [cited by applicant]
WO WO2008083174A2 · 2008 [cited by applicant]
WO WO2008085562A2 · 2008 [cited by applicant]
WO WO2008116078A2 · 2008 [cited by applicant]
WO WO2008156712A1 · 2008 [cited by applicant]
WO WO2009046738A1 · 2009 [cited by applicant]
WO WO2009053041A2 · 2009 [cited by applicant]
WO WO2009118296A2 · 2009 [cited by applicant]
WO WO2009129227A1 · 2009 [cited by applicant]
WO WO2010037395A2 · 2010 [cited by applicant]
WO WO2010037539A1 · 2010 [cited by applicant]
WO WO2010066418A1 · 2010 [cited by applicant]
WO WO2011012316A2 · 2011 [cited by applicant]
WO WO2011143656A2 · 2011 [cited by applicant]
WO WO2012045075A1 · 2012 [cited by applicant]
WO WO2012045082A2 · 2012 [cited by applicant]
WO WO2012135805A2 · 2012 [cited by applicant]
WO WO2012159643A1 · 2012 [cited by applicant]
WO WO2012159729A1 · 2012 [cited by applicant]
WO WO2012159754A2 · 2012 [cited by applicant]
WO WO2013040142A2 · 2013 [cited by applicant]
WO WO2013052523A1 · 2013 [cited by applicant]
WO WO2013090648A1 · 2013 [cited by applicant]
WO WO2013124701A2 · 2013 [cited by applicant]
WO WO2013151663A1 · 2013 [cited by applicant]
WO WO2013151664A1 · 2013 [cited by applicant]
WO WO2013151665A2 · 2013 [cited by applicant]
WO WO2013151672A2 · 2013 [cited by applicant]
WO WO2014012051A1 · 2014 [cited by applicant]
WO WO2014071219A1 · 2014 [cited by applicant]
WO WO2014093924A1 · 2014 [cited by applicant]
WO WO2014144039A1 · 2014 [cited by applicant]
WO WO2014144711A1 · 2014 [cited by applicant]
WO WO2014144767A1 · 2014 [cited by applicant]
WO WO2014152027A1 · 2014 [cited by applicant]
WO WO2014152030A1 · 2014 [cited by applicant]
WO WO2014152031A1 · 2014 [cited by applicant]
WO WO2014152211A1 · 2014 [cited by applicant]
WO WO2014159813A1 · 2014 [cited by applicant]
WO WO2014160243A1 · 2014 [cited by applicant]
WO WO2014164253A1 · 2014 [cited by applicant]
WO WO2014168874A2 · 2014 [cited by applicant]
WO WO2014180490A1 · 2014 [cited by applicant]
WO WO2014180569A1 · 2014 [cited by applicant]
WO WO2015014375A1 · 2015 [cited by applicant]
WO WO2015014869A1 · 2015 [cited by applicant]
WO WO2015034925A1 · 2015 [cited by applicant]
WO WO2015034928A1 · 2015 [cited by applicant]
WO WO2015038892A1 · 2015 [cited by applicant]
WO WO2015043613A1 · 2015 [cited by applicant]
WO WO2015051169A2 · 2015 [cited by applicant]
WO WO2015051173A2 · 2015 [cited by applicant]
WO WO2015058780A1 · 2015 [cited by applicant]
WO WO2015085318A2 · 2015 [cited by applicant]
WO WO2015089511A2 · 2015 [cited by applicant]
WO WO2015117620A1 · 2015 [cited by applicant]
WO WO2015164674A1 · 2015 [cited by applicant]
WO WO2015172843A1 · 2015 [cited by applicant]
WO WO2016062323A1 · 2016 [cited by applicant]
WO WO2016091391A1 · 2016 [cited by applicant]
WO WO2016107877A1 · 2016 [cited by applicant]
WO WO2016128060A1 · 2016 [cited by applicant]
WO WO2016128376A1 · 2016 [cited by applicant]
WO WO2016155809A1 · 2016 [cited by applicant]
WO WO2017106638A1 · 2017 [cited by applicant]
WO WO2018195357A1 · 2018 [cited by applicant]
WO WO2018224166A1 · 2018 [cited by applicant]
WO WO2018224405A1 · 2018 [cited by applicant]
WO WO2018227030A1 · 2018 [cited by applicant]
WO WO2019050994A1 · 2019 [cited by applicant]
WO WO2019075112A1 · 2019 [cited by applicant]
WO WO2019104203A1 · 2019 [cited by applicant]
WO WO2019168984A1 · 2019 [cited by applicant]
Vormehr et al., Current Opinion in Immunology vol. 39, pp. 14-22 (Year: 2016). [cited by examiner]
Kreiter, S., et al. Nature 520, 692-696 (Year: 2015). [cited by examiner]
Kreiter, S. et al., Mutant MHC class II epitopes drive therapeutic immune responses to cancer, Nature, 520(7549):692-6 (2015). [cited by applicant]
Vormehr, M. et al., Mutanome directed cancer immunotherapy, Curr Opin Immunol, 39:14-22 (2016). [cited by applicant]
Castle, J.C. et al., Exploiting the Mutanome for Tumor Vaccination, Amer. Assoc. Canc. Res., 72(5):1081-1091 (2012). [cited by applicant]
International Preliminary Report on Patentability for PCT/EP18/64468 (Methods for Predicting the Usefulness of Disease Specific Amino Acid Modifications for Immunotherapy, filed Jun. 1, 2018), received by ISA/EP, 6 page… [cited by applicant]
International Preliminary Report on Patentability for PCT/EP2017/064140, (Methods for Predicting the Usefulness of Disease Specific Amino Acid Modifications for Immunotherapy, filed Jun. 9, 2017) received by ISA/EP, 6 p… [cited by applicant]
International Search Report for PCT/EP18/64468 (Methods for Predicting the Usefulness of Disease Specific Amino Acid Modifications for Immunotherapy, filed Jun. 1, 2018), received by ISA/EP, 5 pages (Jul. 6, 2018). [cited by applicant]
International Search Report for PCT/EP2017/064140, (Methods for Predicting the Usefulness of Disease Specific Amino Acid Modifications for Immunotherapy, filed Jun. 9, 2017) received by ISA/EP, 5 pages (Mar. 21, 2018). [cited by applicant]
Jorgensen, L. et al., Recent trends in stabilising peptides and proteins in pharmaceutical formulation—considerations in the choice of excipients, Expert Opin. Drug Deliv., 6(11):1219-1230 (2009). [cited by applicant]
Muralidhara, B. K. et al., Critical considerations for developing nucleic acid macromolecule based drug products, Drug Discovery Today, 21(3):430-444 (2016). [cited by applicant]
Written Opinion for PCT/EP18/64468 (Methods for Predicting the Usefulness of Disease Specific Amino Acid Modifications for Immunotherapy, filed Jun. 1, 2018), received by ISA/EP, 5 pages (Jul. 6, 2018). [cited by applicant]
Written Opinion for PCT/EP2017/064140, (Methods for Predicting the Usefulness of Disease Specific Amino Acid Modifications for Immunotherapy, filed Jun. 9, 2017) received by ISA/EP, 5 pages (Mar. 21, 2018). [cited by applicant]
Morse, M. et al., An Alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer, The Journal of Clinical Investigation, 12… [cited by applicant]
Abastado, J.P. et al., Differential role of conserved and polymorphic residues of the binding groove of MHC class I molecules in the selection of peptides, J Immunol., 151(7):3569-75 (1993). [cited by applicant]
Abrams, S. et al., Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4 [cited by applicant]
Adzhubei, A. et al., A method and server for predicting damaging missense mutations. Nat Methods. 7(4):248-9 (2010). [cited by applicant]
Ajay, S. et al., Accurate and comprehensive sequencing of personal genomes, Genome Res., 21(9):1498-505 (2011). [cited by applicant]
Allard, W.J. et al., Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases, Clin Cancer Res., 10(20):6897-904 (2004). [cited by applicant]
Anderson, M. and Schrijver, I., Next generation DNA sequencing and the future of genomic medicine, Genes (Basel), 1(1):38-69 (2010). [cited by applicant]
Arnold, P.Y. et al., The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues, J Immunol., 169(2):739-49 (2002). [cited by applicant]
Bainbridge, M. et al., Whole exome capture in solution with 3 Gbp of data, Genome Biol., 11(6):R62 (2010). [cited by applicant]
Bentley, D. et al., Accurate whole human genome sequencing using reversible terminator chemistry, Nature, 456(7218):53-59 (2008). (Author Manuscript). [cited by applicant]
Berensmeier, Sonja, Magnetic particles for the separation and purification of nucleic acids, Appl Microbiol Biotechnol., 73(3):495-504 (2006). [cited by applicant]
Berger, M. et al., Integrative analysis of the melanoma transcriptome, Genome Res., 20(4):413-27 (2010). [cited by applicant]
Bijker, M. et al., CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity, J Immunol., 179(8):5033-40 (2007). [cited by applicant]
Bloom, M. et al., Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma, J Exp Med., 185(3):453-9 (1997). [cited by applicant]
Bobisse, S. et al., Neoantigen-based cancer immunotherapy, Ann Transl Med., 4(14):262 (2016). [cited by applicant]
Boczkowski, D. et al., Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo, J Exp. Med., 184:465-472 (1996). [cited by applicant]
Bogojeska et al. Rtreemix: an R package for estimating evolutionary pathways and genetic progression scores Bioinformatics, 24(20);2391-2392 (2008). [cited by applicant]
Boisguérin, V. et al., Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside, Br J Cancer, 111(8):1469-75 (2014). [cited by applicant]
Bowerman, N. et al., Engineering the binding properties of the T cell receptor: peptide: MHC ternary complex that governs T cell activity, Mol. Immun., 46:3000-3008 (2009). [cited by applicant]
Brennick et al., Neoepitopes as cancer immunotherapy targets: key challenges and opportunities, Immunotherapy, 9(4):361-371 (2017). [cited by applicant]
Brickner, A. et al., The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing, J Exp Med., 193(2):195-206 (2001). [cited by applicant]
Brinckerhoff, L. et al., Melanoma vaccines, Current Opinion Oncology, 12(2):163-173 (2000). [cited by applicant]
Brochet, X. et al., IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis, Nucleic Acids Res., 36:W503-8 (2008). [cited by applicant]
Buckwalter, M. and Srivastava, P., It is the antigen(s), stupid and other lessons from over a decade of vaccitherapy of human cancer, Semin Immunol, 20(5):296-300 (2008). [cited by applicant]
Byers, Tim, What can randomized controlled trials tell us about nutrition and cancer prevention?, CA Cancer J Clin., 49(6):353-61 (1999). [cited by applicant]
Campbell, P. et al., The patterns and dynamics of genomic instability in metastatic pancreatic cancer, Nature, 467(7319):1109-13 (2010). [cited by applicant]
Carbone, D. et al., Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome, J Clin Oncol., 23(22):5099-107 (2005). [cited by applicant]
Carralot, J. et al., Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas, Genetic Vaccines and Therapy, 3(6): 10 pages (2005). [cited by applicant]
Carreno, B.M. et al., Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells, Science, 348(6236):803-8 (2015). [cited by applicant]
Carter, P. et al., Identification and validation of cell surface antigens for antibody targeting in oncology, Endocrine-Related Cancer, 11(4):659-687 (2004). [cited by applicant]
Chang, S. et al., Peptide length-based prediction of peptide-MHC class II binding, Bioinformatics, 22(22):2761-2767 (2006). [cited by applicant]
Choi, M. et al., Genetic diagnosis by whole exome capture and massively parallel DNA sequencing, Proc Natl Acad Sci USA, 106(45):19096-101 (2009). [cited by applicant]
Communication (1) of a notice of opposition for EP12723117.3, 34 pages (Apr. 20, 2020). [cited by applicant]
Communication (2) of a notice of opposition for EP12723117.3, 34 pages (Apr. 20, 2020). [cited by applicant]
Communication of a notice of opposition for EP12723117.3, 33 pages (Apr. 17, 2020). [cited by applicant]
Culshaw, S. et al., Assessment of Human Immune Response to Mutans Streptococcal Glucosyltransferase Peptides Selected by MHC Class II Binding Probability, International Journal of Peptide Research and Therapeutics, 13(4… [cited by applicant]
Decision Revoking the European Patent (Art. 101(2) and 101(3)(b) EPC) for EP11781409.5 (EP 2569633B) and associated documents, 39 pages (Nov. 5, 2018). [cited by applicant]
Delamarre, L. et al., Cancer immunotherapy. Neo approaches to cancer vaccines, Science, 348(6236):760-1 (2015). [cited by applicant]
Doctoral Thesis by Marc Günder, 216 pages (2012). [Non-English copy]. [cited by applicant]
Dudley, M.E., et al., Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients, J Immunother., 26(4):332-42 (2003). [cited by applicant]
Ecke, T. et al., TP53 Gene Mutations in Prostate Cancer Progression, Anticancer Research, 30:1579-1586 (2010). [cited by applicant]
Greenblatt, M. et al., Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants, Oncongene, 22:1150-11… [cited by applicant]
Grudzien-Nogalska, E. et al., Synthetic mRNAs with superior translation and stability properties, Methods Mol Biol., 969:55-72 (2013). [cited by applicant]
Gubin, M.M. et al., Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens, Nature, 515(7528):577-81 (2014). [cited by applicant]
Hacohen, N. et al., Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines, Cancer Immunol Res, 1:11-15 (2013). (Author Manuscript). [cited by applicant]
Hirano, J. et al., Hepatitis C virus modulates signal peptide peptidase to alter host protein processing, Proc Natl Acad Sci USA, 118(22):e2026184118, 12 pages (2021). [cited by applicant]
Hodges, E. et al., Genome-wide in situ exon capture for selective resequencing, Nat Genet., 39(12):1522-7 (2007). [cited by applicant]
Hodis, E. et al., A landscape of driver mutations in melanoma, Cell, 150(2):251-63 (2012). [cited by applicant]
Holtkamp, S. et al., Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells, Blood, 108(13):4009-17 (2006). [cited by applicant]
Hoyt, M.A. et al., Glycine-alanine repeats impair proper substrate unfolding by the proteasome, EMBO J., 25(8):1720-9 (2006). [cited by applicant]
International Search Report for PCT/EP2015/053021, 6 pages (Aug. 18, 2016). [cited by applicant]
International Search Report for PCT/EP2016/052684, 6 pages (Aug. 18, 2016). [cited by applicant]
Jordan, K. et al., Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens, PNAS, 107(10):4652-4657 (2010). [cited by applicant]
Kartikasari, A. et al., Therapeutic Cancer Vaccines—T Cell Responses and Epigenetic Modulation, Frontiers in Immunology, 9:1-15 (2019). [cited by applicant]
Katsnelson, Alla, Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment, Nat Med., 22(2):122-4 (2016). [cited by applicant]
Kawakami, Y. et al., Identification of human tumor antigens and its implications for diagnosis and treatment of cancer, Cancer Sci, 95(10):784-791 (2004). [cited by applicant]
Kent, James W., BLAT—the BLAST-like alignment tool, Genome Res., 12(4):656-64 (2002). [cited by applicant]
Kim, Y. et al., Immune epitope database analysis resource, Nucleic Acids Res., 40:W525-30 (2012). [cited by applicant]
Koido, S. et al., Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)-Specific MHC Class I/II-Restricted Epitopes for Pancreatic Cancer, Clinical Cancer Research, 20(16):4228-4239 (… [cited by applicant]
Koressaar, T. and Remm, M., Enhancements and modifications of primer design program Primer3, Bioinformatics, 23(10):1289-91 (2007). [cited by applicant]
Kranz, L.M. et al., Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy, Nature, 534(7607):396-401 (2016). [cited by applicant]
Kreiter, S. et al., Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals, J Immunol., 180(1):309-18 (2008). [cited by applicant]
Kronenberger, K. et al., A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia, J Immunother, 31(8):723-730 (2008). [cited by applicant]
Kuhn, A.N. et al., Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo, Gene Ther., 17(8):961-71 (2010). [cited by applicant]
Langmead, B. et al., Ultrafast and memory-efficient alignment of short DNA sequences to the human genome, Genome Biol., 10(3):R25 (2009). [cited by applicant]
Lawrence, M.S. et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499(7457):214-218 (2013). [cited by applicant]
Le Calvez-Kelm, F. et al., Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study, Br… [cited by applicant]
Le, D.T et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N Engl J Med., 372(26):2509-20 (2015). [cited by applicant]
Li, H. and Durbin, R., Fast and accurate short read alignment with Burrows-Wheeler transform, Bioinformatics, 25(14):1754-60 (2009). [cited by applicant]
Linard, B. et al., A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion, J Immunol., 168(9):4802-4808 (2002). [cited by applicant]
Lundegaard, C. et al., NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11, Nucleic Acids Research, 36:w509-w512, (2008). [cited by applicant]
Lundegaard, C. et al., State of the art and challenges in sequence based T-cell epitope prediction, Immunome Res., 6 Suppl 2(Suppl 2):S3 (2010). [cited by applicant]
Malcikova, J. et al., Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia, Mol Immunol., 45(5):1525-1529 (2008). [cited by applicant]
Maloy, K.J. et al., Intralymphatic immunization enhances DNA vaccination, Proc Natl Acad Sci USA, 98(6):3299-303 (2001). [cited by applicant]
Mardis, E. and Wilson, R., Cancer genome sequencing: a review, Hum Mal Gen, 18:R163-R168 (2009). [cited by applicant]
Margulies, M., Genome Sequencing in Open Microfabricated High Density Picoliter Reactors, Nature, 437:376-380 (2005). [cited by applicant]
Mcgranahan, N. et al., Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, 351(6280):1463-9 (2016). [cited by applicant]
Meleif, C. and Van Der Burg, S., Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines, Nature Reviews, 8:351-360 (2008). [cited by applicant]
Men, Y. et al., Assessment of Immunogenicity of Human Melan-A Peptide Analogues in HLA-A*0201/Kb Transgenic Mice, The Journal of Immunology, 162(6):3566-3573 (1999). [cited by applicant]
Mortazavi, A. et al., Mapping and quantifying mammalian transcriptomes by RNA-Seq, Nat Methods., 5(7):621-8 (2008). [cited by applicant]
Nagrath, S. et al., Isolation of rare circulating tumour cells in cancer patients by microchip technology, Nature, 450(7173):1235-9 (2007). [cited by applicant]
NG, P. et al., Genetic Variation in an Individual Human Exome, PLoS Gen., 4(8): 1-15, 2008. [cited by applicant]
Notice of Opposition to EP 2569633 B (Application No. EP11781409.5) and associated documents (Agenus Inc.), 20 pages (Nov. 9, 2016). [cited by applicant]
Notice of Opposition to EP 2569633 B (Application No. EP11781409.5) and associated documents (Dr. Christian Muller) , 49 pages (Nov. 9, 2016). [cited by applicant]
Notice of Opposition to EP 2569633 B (Application No. EP11781409.5) and associated documents (Gritstone Oncology, Inc.), 53 pages (Nov. 7, 2016). [cited by applicant]
Notice of Opposition to EP 2569633 B (Application No. EP11781409.5) and associated documents (James Poole Limited), 35 pages (Nov. 9, 2016). [cited by applicant]
Notice of Opposition to EP 2569633 B (Application No. EP11781409.5) and associated documents (Strawman Limited) , 39 pages (Nov. 10, 2016). [cited by applicant]
Novellino et al., A listing of human tumor antigens recognized by T cells: Mar. 2004 update, Cancer Immunol Immunother, 2005, 54: 187-207. [cited by applicant]
Omokoko, T.A., et al., Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity, J Immunol Res., 9540975, 13 pages (2016). [cited by applicant]
Otrashewvskaya, E.V. et al., Progress in the Development of Vaccines for the Prevention of Chikungunya Disease and Outlooks for Market Appearance, BIOproducts, Prevention, Diagnostics, Treatment, 23 pages English Abstra… [cited by applicant]
Ott, P. et al., Vaccines and melanoma, Hematol Oncol Clin North Am, 28(3):559-569 (2014). [cited by applicant]
Overwijk, W. et al., Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors, J Immunother Cancer, 1:11, 4 pages (2013). [cited by applicant]
Pascolo, S., Messenger RNA-based vaccines, Expert Opin. Biol. Ther., 4(8):1285-1294 (2004). [cited by applicant]
Pleasance, E. et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature, 463: 184-190, 2010. [cited by applicant]
Pleasance, E.D. et al., A comprehensive catalogue of somatic mutations from a human cancer genome, Nature, 463(7278):191-6 (2010). [cited by applicant]
Rajasagi, M. et al., Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia, Blood, 124(3):453-462 (2014). [cited by applicant]
Rizvi, N. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Cancer Immunology, 348(6230):124-128 (2014). [cited by applicant]
Rizvi, N.A. et al., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348(6230):124-8 (2015). [cited by applicant]
Robbins, P. et al., A mutated ß-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes, J Exp Med., 183(3):1185-1192 (1996). [cited by applicant]
Robbins, P.F. et al., Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells, Nat Med., 19(6):747-52 (2013). [cited by applicant]
Ronaghi, M. et al., A sequencing method based on real-time pyrophosphate, Science, 281(5375):363, 365 (1998). [cited by applicant]
Saeterdal, I. et al., Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer, Proc Natl Acad Sci USA, 98(23):13255-13260 (2001). [cited by applicant]
Sahin, U. and Tureci, O., Personalized vaccines for cancer immunotherapy, Science, 359:1355-1360 (2018). [cited by applicant]
Sallman, D. and Padron, E., Integrating mutation variant allele frequency into clinical practice in myeloid malignancies, Hematol Oncol Stem Cell Ther., 9:89-95 (2016). [cited by applicant]
Sampson, J. et al., An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme, Mol Cancer Ther., 8(10):2773-2779 (2009). [cited by applicant]
Schaffner, C. et al., Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia, Blood, 94(2):748-753 (1999). [cited by applicant]
Scheibenbogen, C. et al., Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ-ELISPOT assay, Int. J. Cancer, 71:932-936 (1997). [cited by applicant]
Schietinger et al., Specificity in cancer immunotherapy, Semin Immunol., 2008, 20(5):276-285, Oct. 2008. [cited by applicant]
Schlessinger, A. and Rost, B., Protein flexibility and rigidity predicted from sequence, Proteins, 61(1):115-26 (2005). [cited by applicant]
Schoenberger, S.P. et al., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions, Nature, 393(6684):480-3 (1998). [cited by applicant]
Schumacher, T. et al., A vaccine targeting mutant IDH1 induces antitumour immunity, Nature, 512:324-327 (2014). [cited by applicant]
Schumacher, T. N. and Schreiber, R. D., Neoantigens in cancer immunotherapy, Science, 348(6230): 69-74 (2015). [cited by applicant]
Schwitalle, Y. et al., Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells, Cancer Immun., 4:14, 10 pages (2004). [cited by applicant]
Shirai, M. et al., Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs, J Immunol., 152(2):549-56 (1994). [cited by applicant]
Simon, P. et al., Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes, Cancer Immunol Res., 2(12):1230-44 (2014). [cited by applicant]
Singh-Jasuja, H. et al., The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy, Cancer Immunol Immunother., 53:187-195 (2004). [cited by applicant]
Snyder, A. et al., Genetic basis for clinical response to CTLA-4 blockade in melanoma, N. Engl. J. Med., 371(23):2189-2199 (2014). [cited by applicant]
Srivastava, N. and Srivastava, P., Modeling the Repertoire of True Tumor-Specific MHC I Epitopes in a Human Tumor, Plos One, 4:1-7 (2009). [cited by applicant]
Stratton, M. et al., The cancer genome, Nature, 458(7239):719-724 (2009). [cited by applicant]
Suhrbier, Andreas, Multi-epitope DNA vaccines, Immunology and Cell Biology, 75:402-408 (1997). [cited by applicant]
Suhrbier, Andreas, Polytope vaccines for the codelivery of multiple CD8 T-cell epitopes, Expert Rev. Vaccines, 1(2):207-213 (2002). [cited by applicant]
Teer, J.K. and Mullikin, J.C., Exome sequencing: the sweet spot before whole genomes, Hum Mol Genet., 19(R2):R145-51 (2010). [cited by applicant]
Tong, J. C. et al., Methods and protocols for prediction of immunogenic Briefings in Bioinformatics, 8(2):96-108 (2006). [cited by applicant]
Tourdot, S. et al., A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes, Eur. J. Immunol., 30(12):3411-3421 (2000). [cited by applicant]
Tran, E. et al., Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer, Science, 344(6184):641-5 (2014). [cited by applicant]
Tran, E. et al., T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer, N Engl J Med., 375(23):2255-2262 (2016). [cited by applicant]
Tureci, O. et al., Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines, Clin Cancer Res., 22(8):1885-96 (2016). [cited by applicant]
Untergasser, A., et al., Primer3—new capabilities and interfaces, Nucleic Acids Res., 40(15):e115 (2012). [cited by applicant]
Van Allen, E.M. et al., Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, 350(6257):207-211 (2015). [cited by applicant]
Van Rooji, N. et al., Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma, J Clin Oncol., 31(32):e439-e442 (2013). [cited by applicant]
Voelkerding, K.V. et al., Next-generation sequencing: from basic research to diagnostics, Clin Chem., 55(4):641-58 (2009). [cited by applicant]
Volpe, G. et al., Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches, Cance… [cited by applicant]
Vormehr, M. et al., Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination, J. Immunol. Res., Article ID 595363, 6 pages (2015). [cited by applicant]
Wang, Rong-Fu, Tumor antigens discovery: perspectives for cancer therapy, Mol Med, 3(11):716-731 (1997). [cited by applicant]
Weinschenk, T. et al., Integrated Functional Genomics Approach for the Design of Patient-individual Antitumor Vaccines, Cancer Research, 62(20):5818-5827 (2002). [cited by applicant]
Wick, DA. et al., Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer, Clin Cancer Res, 20(5):1125-34 (2014). [cited by applicant]
Wolchok, J.D., et al., Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res., 15(23):7412-20 (2009). [cited by applicant]
Wood, L. et al., The Genome Landscapes of Human Breast and Colorectal Cancers, Science, 318(5853):1108-1113 (2007). [cited by applicant]
Written Opinion for PCT/EP2015/053021, 6 pages (Aug. 18, 2016). [cited by applicant]
Written Opinion for PCT/EP2016/052684, 5 pages (Aug. 18, 2016). [cited by applicant]
Yadav, M. et al., Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing, Nature, 515(7528):572-6 (2014). [cited by applicant]
Yokoyama, Y, et al., Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells, Clin Cancer Res, 14(17):5503-5511 (2008). [cited by applicant]
Zhang, J. et al., The impact of next-generation sequencing on genomics, J. Genet. Genomics, 38(3):95-109 (2011). [cited by applicant]
Zhang, M. and Coffino, P., Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing, J Biol Chem., 279(10):8635-41 (2004). [cited by applicant]
Zhu, S. et al., Improving MHC binding peptide prediction by incorporating binding data of auxiliary MHC molecules, Bioinformatics, 22(13):1648-55 (2006). [cited by applicant]
Agrawal, S., Antisense oligonucleotides: towards clinical trials, Trends Biotechnol., 14(10):376-87 (1996). [cited by applicant]
Aly, Hamdy A.A., Cancer Therapy and Vaccination, Journal of Immunological Methods, 382(1):1-23 (2012). [cited by applicant]
Azuma, M. et al., B70 antigen is a second ligand for CTLA-4 and CD28, Nature, 366(6450):76-9 (1993). [cited by applicant]
B16 Melanoma, https://en.wikipedia.org/wiki/B16_Melanoma, retrieved from the internet on Sep. 23, 2016, 3 pages. [cited by applicant]
Bansal, Vikas, A statistical method for the detection of variants from next-generation resequencing of DNA pools, Bioinformatics 26, 318-324 (2010). [cited by applicant]
Bei, R. and Scardino, A., TAA Polyepitope DNA-Based Vaccines: A Potential Tool for Cancer Therapy, Journal of Biomedicine and Biotechnology, 2010, 12 pages (2010). [cited by applicant]
Bei, R., et al., The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice, J Immunother., 21(3):159-69 (1998). [cited by applicant]
Bocchia, M. et al., Antitumor Vaccination: Where We Stand, Haematologica, 85(11):1172-1206 (2000). [cited by applicant]
Breiman, Leo, Statistical Modeling: The Two Cultures, Statistical Science, 16(3):199-231 (2001). [cited by applicant]
Buonaguro, L. et al., Translating Tumor Antigens into Cancer Vaccines, Clinical and Vaccine Immunology, 18(1):23-34 (2011). [cited by applicant]
Cai, A. et al., Peptides Derived from Mutated BCR-ABL Elicit T Cell Immunity in CML Patients, Blood, 116(21):388-388 (2010). [cited by applicant]
Chang, H. et al., Exome Sequencing Reveals Comprehensive Genomic Alterations across Eight Cancer Cell Lines, PLOS ONE, 6(6): e21097, 9 pages (2011). [cited by applicant]
Chapman, M. et al., Applications of Next-Generation Sequencing to Blood and Marrow Transplantation, Biology of Blood and Marrow Transplantation, 18(1):S151-S160 (2012). [cited by applicant]
Chenchik, A. et al., Generation and use of high quality cDNA from small amounts of total RNA by SMART PCR, Gene Cloning and Analysis by RT-PCR, pp. 305-319 (1998). [cited by applicant]
Chmielecki, J. et al., Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer, Nucleic Acids Research, pp. 1-1… [cited by applicant]
Conry, R. et al., Characterization of a messenger RNA polynucleotide vaccine vector, Cancer Res,. 55:1397-1400 (1995). [cited by applicant]
Conry, R. et al., Immune response to a carcinoembryonic antigen polynucleotide vaccine, Cancer Res., 54:1164-1168 (1994). [cited by applicant]
Coulie, P. et al., A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma, Proc. Natl. Acad. Sci. USA, 92:7976-7980 (1995). [cited by applicant]
Dahl, F. et al., Multigene amplification and massively parallel sequencing for cancer mutation discovery, PNAS, 104:9387-9392 (2007). [cited by applicant]
Dang, C. et al., Replacement Matrix: a web server for maximum-likelihood estimation of amino acid replacement rate matrices, Bioinformatics, 27(19):2758-2760 (2011). [cited by applicant]
Datta, S. et al., A Subset of Toll-Like Receptor Ligands Induces Cross-presentation by Bone Marrow-Derived Dendritic Cells, J Immunol, 170:4102-10 (2003). [cited by applicant]
De Groot A. and Moise L., Prediction of immunogenicity for therapeutic proteins: state of the art, Curr Opin Drug Discov Devel., 10(03):332-340 (2007). [cited by applicant]
Del Val, M. et al., Efficient Processing of an Antigenic Sequence for Presentation by MHC Class I Molecules Depends on Its Neighboring Residues in the Protein, Cell, 66(6,):1145-1153 (1991). [cited by applicant]
Dengjel, J et al., Glycan side chains on naturally presented MHC class II ligands, J Mass Spectrom, 40:100-104 (2005). [cited by applicant]
Dennis, Carina, Off by a whisker, Nature, 442:739-741 (2006). [cited by applicant]
Depristo, M. et al., A framework for variation discovery and genotyping using next-generation DNA sequencing data, Nature Genetics 43, 491-498 (2011). [cited by applicant]
Dey, N. et al., The Protein Phosphatase Activity of PTEN Regulates Src Family Kinases and Controls Glioma Migration, Cancer Res., 68:1862-71 (2008). [cited by applicant]
Ding, F. et al., Multiepitope Peptide-Loaded Virus-Like Particles as a Vaccine Against Hepatitis B Virus-Related Hepatocellular Carcinoma, Hepatology, 49(5):1492-1502 (2009). [cited by applicant]
Ding, L. et al., Analysis of next-generation genomic data in cancer: accomplishments and challenges, Human Molecular Genetics, 19(2):R188-R196 (2010). [cited by applicant]
Ding, L. et al., Genome remodeling in a basal-like breast cancer metastasis and xenograft, Nature, 464:999-1005 (2010). [cited by applicant]
Dolgin, Elie, The Billion-Dollar Biotech, Nature, 522:26-28 (2015). [cited by applicant]
Druley, T.E. et al., Quantification of rare allelic variants from pooled genomic DNA, Nature Methods, 6(4):263-265 (2009). [cited by applicant]
Echchakir, H. et al., A Point Mutation in the α-Actinin-4 Gene Generates an Antigenic Peptide Recognized by Autologous Cytolytic T Lymphocytes on a Human Lung Carcinoma, Cancer Res, 61:4078-83 (2001). [cited by applicant]
Ewen, K. et al., Identification and Analysis of Error Types in High-Throughout Genotyping, Am. J. Hum. Genet., 67:727-736 (2000). [cited by applicant]
Fawcett, Tom, An introduction to ROG analysis, Pattern Recognition Letters, 27(8):861-874 (2006). [cited by applicant]
Feng, D.F. et al., Aligning amino acid sequences: comparison of commonly used methods, J Mol. Evol., 21(2):112-125 (1985). [cited by applicant]
Florea et al., Proceedings of Computational System Bioinformatics, 2:1-10 (2003). [cited by applicant]
Fotin-Mleczek, M. et al., Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity, J. Immunotherapy; 34(1):1-15 (2011). [cited by applicant]
Fritsch, E. et al., HLA-Binding Properties of Tumor Neoepitopes in Humans, Cancer Immunology Research, 2:522-529 (2014). [cited by applicant]
Frumkin, D. et al., Cell Lineage Analysis of a Mouse Tumor, Cancer Research 68:5924-5931 (2008). [cited by applicant]
Fujita, P. et at., The UCSC Genome Browser database: update 2011, Nucleic Acids Research, 39:876-882 (2011). [cited by applicant]
Gjertsen, Marianne K., Mutated ras peptides as vaccines in immunotherapy of cancer, Vox Sanguinis, 74(2):489-495 (1998). [cited by applicant]
Gnirke, A. et al., Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing, Nat. Biotechnol, 27:182-9 (2009). [cited by applicant]
Goya, R. et al., SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors, Bioinformatics, 26:730-736 (2010). [cited by applicant]
Gryaznov, Sergei M., Oligonucleotide N3′ → P5′ phosphoramidates as potential therapeutic agents, Biochimica Biophysica Acta, 1489:131-140 (1999). [cited by applicant]
Cited By (1)
US 12,545,928